Elunetirom
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Elunetirom, also known by its developmental code names ABX-002 and MA-JD21, is a thyroid hormone receptor agonist which is under development for the treatment of major depressive disorder, bipolar depression, multiple sclerosis, and adrenomyeloneuropathy.[1][2] It is a prodrug of LL-340001 and acts as a potent, selective, and centrally penetrant agonist of the thyroid hormone receptor beta (TRβ).[1][2] The drug produces psychoplastogenic effects similar to those of brain-derived neurotrophic factor (BDNF) in rodents.[2] In addition, it has been found to improve cognitive impairment caused by old age or scopolamine treatment in rodents.[2] Eunetirom is under development by Autobahn Therapeutics.[1] As of December 2025, it is in phase 2 clinical trials for treatment of major depressive disorder and bipolar depression and is in the preclinical research stage of development for multiple sclerosis and adrenomyeloneuropathy.[1]
| |
| Clinical data | |
|---|---|
| Other names | ABX-002; ABX002; MA-JD21; MA-JD-21 |
| Routes of administration | Oral[1] |
| Drug class | Thyromimetic; Thyroid hormone receptor beta (TRβ) agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H21Cl2NO3 |
| Molar mass | 382.28 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
